O-11: Once-Weekly insulin efsitora achieves comparable A1C reduction to daily insulin therapy
F AbbasAbstract
Introduction
Type 1 Diabetics requires Insulin to keep the blood glucose levels within normal range as body no longer produces Insulin and requires exogenous source.Insulin efistora is a new insulin preperation used once weekly to treat Diabetes.
Objectives
To determine the efficacy of once weekly Insulin Efistora in Young adults who used insulin for the first time, previously used daily basal insulin and mealtime insulin respectively.
Methods
We conducted a 52-week, phase 3, parallel-design, open-label, treat-to-target trial involving Young adults(16-18 yrs old) who had not previously received Insulin. We had fixed dose titration of insulin efistora in 217 participants and they were randomly assigned in a 1:1 ratio to receive efsitora or degludec.The primary end point was the change in the Glycated hemoglobin level from baseline to week 52; we hypothesized that Efsitora would be noninferior to Degludec.The percentage of time that the glucose level was in the target range of 70 to 180 mg per deciliter in weeks 48 through 52.The fixed-dose titration done for Efsitora to once-daily insulin Degludec, with the goal of determining whether it could offer comparable blood glucose management.
Results
The study showed once-weekly Insulin Efsitora lowered blood glucose just as well as daily insulin Degludec after 52 weeks. Efsitora dropped A1C levels by 1.31%, reaching an average A1C of 6.92%, compared to a 1.27% reduction and A1C of 6.96% with insulin Degludec. A second analysis, which looked at results based on how patients followed the treatment, showed similar findings: efsitora reduced A1C by 1.19% (to 7.05%) versus a 1.16% reduction (to 7.08%) with Degludec.
Conclusions
In Young adults who had not previously received Insulin, Once-weekly Efsitora was noninferior to once-daily Degludec in reducing Glycated hemoglobin levels.